Author:
Liu Ying,Lu Cun-Yu,Zheng Yi,Zhang Yu-Min,Qian Ling-Ling,Li Ku-Lin,Tse Gary,Wang Ru-Xing,Liu Tong
Abstract
Diabetes mellitus is a prevalent disorder with multi-system manifestations, causing a significant burden in terms of disability and deaths globally. Angio-tensin receptor-neprilysin inhibitor (ARNI) belongs to a class of medications for treating heart failure, with the benefits of reducing hospitalization rates and mortality. This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications, discussing possible physiological and molecular mechanisms, with insights for future applications.
Publisher
Baishideng Publishing Group Inc.